What is Zacks Research’s Estimate for Novartis Q1 Earnings?

Novartis AG (NYSE:NVS) – Stock analysts at Zacks Research decreased their Q1 2028 earnings estimates for Novartis in a research report issued to clients and investors on Friday, September 25th. Zacks Research analyst Team now anticipates that the company will post earnings per share of $2.54 for the quarter, down from their previous estimate of $2.55. The consensus estimate for Novartis’ current full-year earnings is $8.87 per share. Zacks Research also issued estimates for Novartis’ FY2028 earnings at $10.69 EPS.

Novartis (NYSE:NVS) last issued its quarterly earnings data on Tuesday, June 30th. The company reported $2.41 earnings per share for the quarter. The company had revenue of $14.95 billion for the quarter. Novartis had a net margin of 23.29% and a return on equity of 38.56%.

NVS has been the topic of a number of other research reports. Citigroup reiterated a “buy” rating on shares of Novartis in a research report on Wednesday, July 22nd. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Novartis in a research note on Friday, July 24th. The Goldman Sachs Group reiterated a “sell” rating on shares of Novartis in a report on Monday, September 21st. Royal Bank Of Canada initiated coverage on shares of Novartis in a research report on Tuesday, September 8th. They set a “sector perform” rating for the company. Finally, HSBC upgraded shares of Novartis from a “reduce” rating to a “hold” rating and raised their price target for the stock from $123.00 to $136.00 in a report on Thursday, September 10th. Six equities research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, Novartis currently has a consensus rating of “Hold” and a consensus target price of $148.40.

Novartis Stock Down 0.9%

Shares of NYSE:NVS opened at $145.56 on Tuesday. The firm has a market cap of $277.75 billion, a P/E ratio of 21.95, a P/E/G ratio of 2.84 and a beta of 0.45. Novartis has a 12-month low of $121.57 and a 12-month high of $170.46. The business has a fifty day simple moving average of $151.45 and a 200 day simple moving average of $151.08. The company has a quick ratio of 0.67, a current ratio of 0.86 and a debt-to-equity ratio of 0.89.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. QRG Capital Management Inc. lifted its stake in shares of Novartis by 9.0% in the 2nd quarter. QRG Capital Management Inc. now owns 164,478 shares of the company’s stock valued at $25,777,000 after purchasing an additional 13,634 shares during the period. Envestnet Portfolio Solutions Inc. grew its stake in Novartis by 3.9% during the second quarter. Envestnet Portfolio Solutions Inc. now owns 19,022 shares of the company’s stock worth $2,981,000 after purchasing an additional 713 shares during the period. Envestnet Asset Management Inc. increased its holdings in Novartis by 0.8% in the second quarter. Envestnet Asset Management Inc. now owns 2,330,979 shares of the company’s stock worth $365,308,000 after purchasing an additional 19,595 shares in the last quarter. Silicon Valley Capital Partners increased its holdings in Novartis by 519.4% in the second quarter. Silicon Valley Capital Partners now owns 192 shares of the company’s stock worth $30,000 after purchasing an additional 161 shares in the last quarter. Finally, Engineers Gate Manager LP acquired a new position in Novartis in the second quarter valued at approximately $4,529,000. 13.12% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Novartis

Here are the key news stories impacting Novartis this week:

• Positive Sentiment: Zacks Research raised its fiscal 2028 earnings-per-share estimate for Novartis to $10.69 from $10.62, suggesting analysts see potential for continued earnings growth beyond the current year. Zacks Research Weighs in on Novartis’ Q1 Earnings
• Positive Sentiment: Analysts continue to identify growth potential in Novartis’ drug portfolio, although the company must demonstrate that new and existing products can offset generic competition. Novartis Has More Growth Ahead
• Neutral Sentiment: Novartis’ GF Score was reported at 78, indicating generally strong financial and operating characteristics, but the stock remains below its 52-week high and around its longer-term moving averages. Novartis Shares and GF Score
• Neutral Sentiment: Zacks Research made only a marginal reduction to its first-quarter 2028 EPS forecast, lowering it to $2.54 from $2.55. The change is too small to materially alter the earnings outlook, while the current-year consensus remains $8.87 per share. Zacks Research Q1 Earnings Estimates
• Negative Sentiment: Pomerantz LLP announced an investigation into potential claims on behalf of Novartis investors. The announcement does not establish wrongdoing, but securities-law investigations can weigh on sentiment and add legal or reputational uncertainty. Pomerantz Novartis Investor Alert
• Negative Sentiment: Investor concerns about generic pressure remain a risk to future sales and margins, particularly if competing products erode revenue from established Novartis medicines. Generic Pressure on Novartis

About Novartis

Novartis AG is a Switzerland-based pharmaceutical company focused on the discovery, development and commercialization of innovative medicines. The company’s research and commercial activities center on cardiovascular, renal and metabolic diseases, immunology, neuroscience, oncology and hematology. Its portfolio includes prescription medicines such as Entresto, Cosentyx, Kesimpta, Kisqali, Pluvicto, Leqvio and Jakavi, as well as other therapies for serious and chronic conditions.

Novartis serves patients and healthcare providers in markets worldwide, with operations spanning North America, Europe, Asia and other international regions.